Plain-English translation of NCT05475613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether anti-PD-1 immunotherapy medications (such as tislelizumab, pembrolizumab, or nivolumab) can shrink advanced liver cancer that is currently too large for transplant. If the cancer shrinks enough, patients may then become candidates for a liver transplant. The study will also use other standard treatments alongside the immunotherapy, tailored to each patient's needs.
Many patients with advanced liver cancer are not eligible for transplant because their tumors are too large or extensive. This trial is testing whether the medication can shrink these cancers enough to make transplant possible, potentially offering a cure to patients who otherwise have very limited options.
You likely qualify if…
You likely don't qualify if…
You would receive the immunotherapy medication every 3-4 weeks by intravenous infusion, possibly combined with other treatments like radiation or targeted drugs, depending on your specific case. The treatment phase lasts up to 12 cycles (roughly 9-12 months). During this time, your doctors will monitor whether your cancer is shrinking using imaging scans and blood tests. If your cancer shrinks enough to meet transplant criteria, you would move to an observation phase before proceeding toward transplant.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China